From theheart.org on Medscape

Coverage from the

European Society of Cardiology (ESC) Congress 2022

August 26 - 29, 2022; Barcelona, Spain and Virtual

August 26 - 29, 2022 Barcelona, Spain and Virtual

ESC 2022 New ESC Guidelines for Cutting CV Risk in Noncardiac Surgery The guidelines, which aim to reduce cardiovascular complications from noncardiac surgery, introduce new concepts and recommendations compared with the previous 2014 document.
Medscape Medical News, September 14, 2022
ESC 2022 Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE Chief among them was a reduction in cardiovascular mortality not observed in the pivotal trial that led to US approval of the drug.
Medscape Medical News, August 29, 2022
ESC 2022 DANCAVAS Hints at Benefit from Comprehensive CV Screening Comprehensive cardiovascular screening fell short of significantly reducing all-cause mortality in men aged 65-74, but some benefits were seen in the whole group and for mortality in those younger than 70.
Medscape Medical News, August 27, 2022

Meeting Highlights At A Glance

TIME: Treatment in Morning versus Evening BP Study, in Brief A study on chronotherapy for blood pressure control, presented at the European Society of Cardiology meeting, has starkly different findings from those of the previous Hygia trial.

Conference News

ESC 2022 Frailty Poses No Limit to HFpEF Meds
MDedge News, September 21, 2022
ESC 2022 New ESC Pulmonary Hypertension Guidelines Urge Earlier Diagnosis
Medscape Medical News, September 20, 2022
ESC 2022 ESC Updates Guidelines for Ventricular Arrhythmia, Sudden Death
Medscape Medical News, September 16, 2022
ESC 2022 Extravascular ICD Surpasses Goals in Pivotal Trial
MDedge News, September 15, 2022
ESC 2022 New ESC Guidelines for Cutting CV Risk in Noncardiac Surgery
Medscape Medical News, September 14, 2022
ESC 2022 PARADISE-MI Obscured As Post Hoc Analysis Finds Flaws
MDedge News, September 14, 2022
ESC 2022 Smartphone AF Screening Doubles Detection: eBRAVE-AF
Medscape Medical News, September 13, 2022
ESC 2022 Heparin Pretreatment May Open Arteries Prior to STEMI Cath
Medscape Medical News, September 13, 2022
ESC 2022 Myocardial Infarction in Women Younger Than 50: Lessons to Learn
Medscape Medical News, September 12, 2022
ESC 2022 GRACE 3.0 Narrows Sex Gap in NSTE-ACS Risk Stratification
Medscape Medical News, September 9, 2022
ESC 2022 'Hot' Plaques on PET Scans Prognostic After MI: PRE-18FFIR
Medscape Medical News, September 8, 2022
ESC 2022 Full-Dose Antithrombotic Aids Selected COVID-19 ICU Patients
Medscape Medical News, September 7, 2022
ESC 2022 Early Signal of Benefit for Empagliflozin in Acute MI: EMMY
Medscape Medical News, September 2, 2022
ESC 2022 MR and PET Perform Similarly in CAD: DanNICAD-2
Medscape Medical News, September 2, 2022
ESC 2022 AI-Assisted Echo Readily Detects Severe Aortic Stenosis
MDedge News, September 1, 2022
ESC 2022 No Invasive Strategy Benefit at 5 Years in ISCHEMIA-CKD EXTEND
Medscape Medical News, September 1, 2022
ESC 2022 PANTHER: Should Clopidogrel Become the 'New Aspirin' in CAD?
Medscape Medical News, September 1, 2022
ESC 2022 Meta-analysis Pins Down Survival Benefit for Transradial Access
Medscape Medical News, August 31, 2022
ESC 2022 Two Old Meds and a DOAC a Bust in COVID-19: The ACT Trials
Medscape Medical News, August 31, 2022
ESC 2022 ARBs, Beta-Blockers Inhibit Marfan Progression Independently
MDedge News, August 31, 2022
ESC 2022 New ESC Cardio-Oncology Guideline Aims to Reduce Cardiotoxicity
Medscape Medical News, August 31, 2022

ESC 2022 Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE
Medscape Medical News, August 29, 2022
ESC 2022 Factor XIa Inhibitor Encouraging in Phase 2 MI, Stroke Studies
Medscape Medical News, August 29, 2022
ESC 2022 No Benefit of Routine Stress Test POST-PCI in High-Risk Patients
Medscape Medical News, August 28, 2022
ESC 2022 Artificial Intelligence Poised to Change CV Risk Prevention
Medscape Medical News, August 28, 2022
ESC 2022 Albuminuria Linked to Higher CVD Risk in Diabetes
Medscape Medical News, August 28, 2022
ESC 2022 COVID-19 Vaccine Safe in Patients With Heart Failure
Medscape Medical News, August 28, 2022
ESC 2022 Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease
Medscape Medical News, August 28, 2022
ESC 2022 AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke
Medscape Medical News, August 28, 2022
ESC 2022 ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease
Medscape Medical News, August 28, 2022
ESC 2022 Artificial Intelligence Beats Sonographers for Echo Accuracy
MDedge News, August 27, 2022
ESC 2022 Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER
MDedge News, August 27, 2022
ESC 2022 DANCAVAS Hints at Benefit from Comprehensive CV Screening
Medscape Medical News, August 27, 2022
ESC 2022 PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2
Medscape Medical News, August 27, 2022
ESC 2022 Vintage Drug Atop Loop Diuretics Boosts ADHF Decongestion: ADVOR
Medscape Medical News, August 27, 2022
ESC 2022 An Hour of Walking Per Week May Boost Longevity in Elderly
Medscape Medical News, August 26, 2022
ESC 2022 Sacubitril/Valsartan Shows Cognitive Safety in Heart Failure
Medscape Medical News, August 26, 2022
ESC 2022 Cannabis for Pain Linked to Slight Risk for Arrhythmia
Medscape Medical News, August 26, 2022
ESC 2022 Secondary CV Prevention Benefit From Polypill Shown
MDedge News, August 26, 2022
ESC 2022 TIME: CV Events Similar With Evening or Morning Dose of BP Meds
Medscape Medical News, August 26, 2022
ESC 2022 NSAIDs Linked to Heart Failure Risk in Diabetes
MDedge News, August 25, 2022
ESC 2022 Barcelona Beckons for First Hybrid ESC Congress
Medscape Medical News, August 19, 2022

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

The Surgeon's Approach to Atrial Fibrillation
John M. Mandrola, MD; Richard Whitlock, MD, PhD
Will Factor XI Be the Goldilocks Anticoagulant Target?
John M. Mandrola, MD;
John W. Eikelboom MBBS, MSc
Updates in Heart Failure From ESC 2022
Wolfram Doehner, MD, PhD
The Skinny on Ultralow LDL-C
Melissa Walton-Shirley, MD; Robert P. Giugliano, MD
Advances in Diabetes and Heart Disease From ESC 2022
Pardeep Jhund, MD
What's the Best Anticoagulation Strategy for COVID-19 Patients?
Michelle L. O'Donoghue, MD, MPH; David D. Berg, MD, MPH
DELIVERing the Details on Dapagliflozin in Heart Failure
Ileana L. Piña, MD, MPH; Scott D. Solomon, MD
Judicious CVD Screening May Work in Men: DANCAVAS
John M. Mandrola, MD
Should Aspirin Be the Second-Line Antiplatelet in CAD?
Michelle L. O'Donoghue, MD, MPH;
Marco Valgimigli, MD, PhD
DANCAVAS: Might Cardiovascular Screening Extend Men's Lives?
Melissa Walton-Shirley, MD;
Axel C.P. Diederichsen, MD, PhD
Bedtime vs Daytime BP Med Dustup: TIME vs HYGIA
Christopher Labos, MD, CM, MSc
PCI Fails in Stable Disease Again: REVIVED-BCIS
John M. Mandrola, MD
Do SGLT2 Inhibitors DELIVER in All Patients With Heart Failure?
John Mandrola, MD
CAPLA Challenges Expert Opinion on Ablation of Persistent AF
John Mandrola, MD
Mandrola Previews His Top 5 Trials From ESC 2022
John Mandrola, MD

Previous Coverage

Popular News from ESC 2021

EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.
Medscape Medical News, Aug 27, 2021
LOOP Trial Undercuts Long-term Continuous ECG Screening for AF It may be that short bouts of AF on long-term continuous monitoring aren't worth seeking out just so anticoagulation can start, even in elderly patients with other risk factors, a study suggests.
Medscape Medical News, Aug 29, 2021
Salt Substitute Reduces Stroke, CV Events, and Death Switching from regular salt to a low-sodium salt substitute has major public health benefits, including a reduction in stroke, cardiovascular events, and death, the new landmark SSaSS shows.
Medscape Medical News, Aug 29, 2021